BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:This event will discuss how emerging biology and cutting-edge 
 technologies are pioneering the medicines of tomorrow. Bringing together 
 scientists\, researchers and entrepreneurs with bold ideas to serve our s
 hared ambitions in creating the next generation of therapeutics to cure m
 ore patients around the world. The 2024 R&amp\;I meeting – based in Manch
 ester – will comprise the following four main sessions.\n\nTrack 1 – Anim
 al-free drug discovery. Emma Shepherd (Aston University) &amp\; Mike Mort
 on (Apconix)\n\nThere has been a major shift away from animal use which h
 as been catapulted by recent legislation stating that the FDA will consid
 er approval of new medicines without animal data. &nbsp\;This session wil
 l showcase some of the latest innovations and applications of animal-free
  technologies including world leading experts who will share their insigh
 ts and experiences on the challenges and opportunities of animal-free dru
 g discovery and development.\n\nTrack 2 – Oncology – Thinking the unthink
 able and drugging the undruggable. Liz Anderson (CRL) &amp\; Susan Critch
 low (AstraZeneca)\n\nIn the ever-evolving landscape of cancer research\, 
 we find ourselves on the precipice of transformative discoveries that wil
 l pave the way for a new generation of cancer therapeutics. &nbsp\;This s
 ession will explore the latest innovations in Oncology drug discovery and
  development and will cover advances in developing antibody-drug conjugat
 es\, RNA modifying enzymes and targeting previously undruggable targets.\
 n\nTrack 3 – New horizons in tackling antimicrobial resistance. Bev Isher
 wood (MDC) &amp\; Lisa Dawson (Charles River Laboratories)\n\nAMR is one 
 of the biggest health challenges we face as a global society\, and it is 
 currently developing faster than the speed of our scientific discoveries.
  There is an urgent need to grow a pipeline of high-quality antimicrobial
  drugs and diagnostics if we are going to address AMR and protect lives w
 orldwide. Antimicrobial Therapies are undergoing a transformation. Simila
 r to that which occurred with the treatment of cancer where innovation ha
 s led to both ‘one for all’ chemotherapies and treatments that target spe
 cific oncogenic pathways\, pathogen and/or indication specific approaches
  to tackle multi-drug resistant infections are being considered. This tra
 nsformation is being enabled by a new wave of innovation in medicines and
  diagnostics discovery. This session will explore the opportunities and c
 hallenges.\n\nTrack 4 – Mass spectrometry and ‘omics. Zack Gurard-Levin (
 Charles River Laboratories) &amp\; Marcus Bantscheff (GSK)\n\nMass spectr
 ometry (MS) continues to gain momentum as a powerful tool in drug discove
 ry and development\, allowing the direct and hypothesis free analysis of 
 the molecular constituents of cells and body fluids. Mass spectrometric m
 easurements provide valuable insights for defining disease states\, targe
 t discovery and validation\, target engagement and mechanisms of bioactiv
 e molecules and drug safety. This session will highlight recent advances 
 in mass spectrometry techniques and their applications in drug discovery\
 , including native MS\, affinity selection mass spectrometry (ASMS)\, and
  chemoproteomics. Learn from experts on how MS can inform on small molecu
 le-target interactions\, elucidation of protein structures\, and the impa
 ct of drugs on cellular pathways.\n\nCONFERENCE DIRECTORS\n\nRoger Clark 
 – Charles River Labs\n\nSarah Brockbank – MDC\n
DTEND:20240321T161500
DTSTAMP:20260512T220029Z
DTSTART:20240320T081500
LOCATION:The University of Manchester\, Oxford Road\, Manchester\, Greater
  Manchester\, M13 9PL\,
SEQUENCE:0
SUMMARY:This event will discuss how emerging biology and cutting-edge tech
 nologies are pioneering the medicines of tomorrow. Bringing together scie
 ntists\,...
UID:e535283c-b8d3-4538-a907-70ac35d67be5
END:VEVENT
END:VCALENDAR